LIMINAL BIOSCIENCES FILES AMENDED SCHEDULE 13E-3 AND SUPPLEMENT TO THE MANAGEMENT INFORMATION CIRCULAR

Posted on by

LAVAL, QC and CAMBRIDGE, England, Sept. 12, 2023 /PRNewswire/ – Liminal BioSciences Inc. (NASDAQ: LMNL) (“Liminal BioSciences” or the “Company”), announced that an amendment to the previously filed Schedule 13E-3 will be filed to address comments raised by the Securities and Exchange…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.